Professor & Chief doctor, Director, Dept. of O&G of Beijing Shijitan Hospital, Supervisor of postgraduates.
M.D. and PhD

Member of Committee of O&G Society of Beijing Medical Association; Executive member of Committee of Tumor Marker Oncology Society of Chinese Anticancer Association; Member of Committee of Gyn Oncology Society of Chinese Anticancer Association; Member of Committee of Fertility & Health Care Society of Chinese Population Association; Member of Committee of Chinese Sexology Association; Active member of American Association for Cancer Research; Editorial Board Member of J. Tumor Marker biology, Journal of Clinical Obstetrics and Gynecology, and Journal of Current Advances in Obstetrics and Gynecology.

M.D. and PhD, in Gynecological Oncology, under the supervision of the famous professor Jiang Sen in Shandong University of Medical Sciences, Jinan, China.
Postdoc researcher, in the affiliated hospital of Academy of Military Medical Sciences for two years.
Visiting Scholar, in Department of Gynecological Oncology and Clinical Oncology, Prince of Wales Hospital of Chinese University of Hong Kong, Hong Kong, China for two years.
Member of Chinese medical team, in Ethiopia for two years.

Professor Li has been an expert in the field of O&G for more than 20 years, accumulating rich clinical practice experiences and acquired solid theoretical knowledge. She can diagnose and treat all kinds of diseases in this field and direct subordinate doctors to diagnose, treat and salvage serious and difficult cases of obstetrics and gynecology. She can also handle complicated and great technical problems, especially in the field of gynecologic oncology, such as surgeries of malignant tumors, complex and difficult tumor operations, minimally invasive surgeries, standardized diagnosis and treatment for gynecologic oncology.

Grants Awarded:
1. Source of Support: Capital Medical and Health Foundation of Beijing City
Project title: Research on the Mechanism of Drug-resistance of Ovarian Carcinoma Cell Line
Total Direct Cost: RMB 800000 (≈US$ 100000)
2. Source of Support: Medical and Health Foundation of Railways Ministry
Project title: Isolation and Identify of New Tumor Marker of EOC
Total Direct Cost: RMB 60000 (≈US$ 7500)

Publications as First and Correspondent Author:
1. Hongxia Li et al. Establishment of taxol-resistance ovarian carcinoma cell line SKOV3/ TAX and study of multidrug resistant mechanism. Sandong Med. 2008(48)6:26-28
2. The expression of COP9, JAK2, HSPS and NADH genes after taxol-chemotherapy on ovarian carcinoma tissues and significance. Chin J Obs&Gyn, China. 2008, in press.
3. Hongxia Li et al .Establishment and gene expression analysis of the human ovarian carcinoma taxol-resistant cell line OC3/TAX300. Tumor, China. 2006(26)8:743-7
4. Hongxia Li et al .Study on the relationship of taxol-resistance of ovarian carcinoma with the amplification of 2p22 on chromosome and the expression of hmsh2 gene. Tumor Prov. Treat Research, China. 2006(33)8:565-7
5. Hongxia Li. Normative treatment of ovarian cancer. J Modern Medicine. 2005,33(1)1-3
6. Dongmei Yin, Hongxia Li, Xinyuan Guan, et al. CGH analysis of ovarian carcinoma cell lines OC3/ PIX3 and OC3/ PIX5. Current Advance Obs & Gyn , China, 2005,14(6)1-3
7. Wenjing Zhang, Hongxia Li, Lei Song, et al. Screening differential expression of taxol-resistance related gene of ovarian carcinnoma by cDNA microarray. J Shandong Med. 2005(45)28:18
8. You-zhen ZHOU, Hongxia Li, Wenjing Zhang .Establishment of topotecan-induced multidrug resistance human epithelial ovarian carcinoma cell line SKOV3/TPT and its biological characteristics. Med J Chin PLA. 2005(30)8:706
9. Hongxia Li et al Establishment of a human ovarian carcinoma taxol- resistant cell lines OC3/PIX3, OC3/ PIX5 and their biological characterization. J Chin Med Research, China. 2004,2(3)1-5
10. Hongxia Li et al .Study on hTERT mRNA expression and telomerase activity in epithelial ovarian carcinomas. J Tumor Marker Oncol. Austria. 2003.18(4)361
11. Hongxia Li et al .Study on the mitochondrion DNA mutation in tumor tissue of gynecologic oncology patients. Chin J Obs & Gyn, China. 2003,38(5)290
12. Hongxia Li et al .Apopotosis gene expression and their relationship to mtDNA mutation in tumor tissues of gynecologic oncology patients. Chin J of birth health & heredity, China. 2003,11(1)34
13. Hongxia Li et al Mutations of p15 P16 gene in ovarian epithelial carcinomas. Chin J Obs & Gyn, China ,2000(35)7:440
14. Hongxia Li et al Study on the homozygous deletions and mutations of P16 gene in ovarian epithelial carcinomas and their clinical significance. Current Advance Obs & Gyn, China, 1998(7)4:392
15. Hongxia Li et al Study on the expression and significance of bcl2 and p53 protein in ovarian epithelial carcinoma. Tumor, China, 1998(18)4:276
16. Hongxia Li et al, Detection of DNA content and its value in evaluation patients prognosis. Current Advance Obs & Gyn, China, 1997(6)2:107
17. Hongxia Li et al. Telomerase activity and their clinical significance in EOC, Bulletin of the Shandong Univer Med Sciences, China, 1999(37)supple:77
18. Hongxia Li et al .Current advance in mtDNA mutation with tumorigeneses research (a literature review). Chin J of birth health & heredity, China. 2002,10(6)125
19. Hongxia Li et al. Current advance in telomerase activity research of ovarian cancer (a literature review). Current Advance Obs & Gyn , China. 2000(9)2:136
20. Hongxia Li et al. Current advance in p16 gene research of ovarian cancer (a literature review). Foreign medical Sciences of Phtho &Clinical Medical ,China. 1999,4:322
21. Hongxia Li et al.Ovarian cancer screening (a literature review). Foreign medical Sciences of Obs & Gyn Medical, China. 1996(23)96
22. Hongxia Li et al. Current advance in molecular research of ovarian cancer (a literature review). Current Advance Obs&Gyn, China. 1995(4)3:260

Monday

Tel: 010-63926260
Fax: 010-68166558
E-mail: lihx69@hotmail.com